What&#x27;s the goal of the project, is it to produce cheap insulin, or is it to validate &quot;open-source biohacking&quot;?<p>If it&#x27;s the latter, why start with such a hard molecule; isn&#x27;t there a lower-hanging fruit?<p>If it&#x27;s the former, it would seem grounded in the assumption that biosimilar insulin unavailability in the Western markets is due to the lack of a royalty-free production method.  I&#x27;m not sure that is the case (and please, correct me along the way).  Biosimilars face a more rigorous&#x2F;expensive approval process than generics (as they should), they&#x27;re more expensive to produce under GxP conditions, and they&#x27;re more expensive to store&#x2F;transport&#x2F;etc—the upfront costs are higher, the production costs are higher, and the logistical costs are higher.  A small portion of NRE costs in the beginning would seem to be a drop in the bucket compared to the rest.  Are you planning to address the rest of the lifecycle?  Also, there would seem to be a lot of handwaving over the folding problem… do you have direct plans to address it?<p>I don&#x27;t intend for this to come across harshly—I&#x27;m genuinely curious and hope this comes across constructively.